PSA: we're really proud of our new Paris Headquarters 😌 Some companies say they care about well-being. We built a whole building around it. 📍 Paris, France
Ipsen
Fabrication de produits pharmaceutiques
Paris, Île-de-France 272 182 abonnés
À propos
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
- Site web
-
http://www.ipsen.com
Lien externe pour Ipsen
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 5 001-10 000 employés
- Siège social
- Paris, Île-de-France
- Type
- Société cotée en bourse
- Domaines
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins et Primary Care
Lieux
Employés chez Ipsen
-
James Frey
GLOBAL PHARMACEUTICALS | Go-To-Market Strategy ~ Brand Development ~ New Product Launch ~ Partnerships & Alliances
-
Frederic Rivart
Consultant IT et Cyber Sécurité
-
Jean-Marc Issa
Head of End User Operations and Services
-
Josep Catlla
Executive Vice President & Chief Corporate Affairs Officer
Nouvelles
-
Surrounding every new medicine is the Regulatory environment and science that foster innovation — and the people who make such innovation work. João Duarte’s recently awarded Fellowships from both Regulatory Affairs Professionals Society (RAPS) and TOPRA - The Organisation for Professionals in Regulatory Affairs recognize not only his personal commitment to Regulatory excellence, but also the team effort behind getting innovative medicines to patients.
-
-
We got everything from "photocopier brand" to "summer music" and “responsible cosmetics”. Nope, nope, and nope. We're actually a global biopharma company developing treatments where they're needed most. Think rare diseases, hard-to-treat cancers, and neurological conditions that don't make headlines but do change lives.
-
Press Release: Ipsen announces strong H1 results — with total sales up by +11.4%* and upgraded guidance of >7% total sales growth for 2025. Learn more: https://lnkd.in/dZeNGmSR
-
-
Press Release: Today, the European Commission has approved a new therapy for the treatment of advanced neuroendocrine tumors. Widely regarded as a complex and uncommon tumor, this approval reinforces our commitment to delivering transformative therapies for people with few options. #Ipsen #oncology #NETs Get the full story → https://lnkd.in/dGCYd-vV
-
-
Press release: We’ve strengthened our Executive Leadership Team with a blend of internal promotions and newly appointed leaders, bringing deep expertise. These appointments reflect our commitment to innovation, and delivering long-term value. Get the full story → https://lnkd.in/dXewhgev
-
-
Caring for people means caring for the planet too. 🌎 What real climate action looks like: → -45% scope 1 & 2 emissions since 2019 (facilities and fleet) → -25% scope 3 emissions since 2019 (suppliers and shipping) → 99.8% renewable electricity → 6x more fully electric vehicles in fleet from 2023 Translation? We're not just greening our own operations. We're transforming our entire network. Because healthy people need a healthy planet.
-
Your new colleague never misses a meeting, towers over everyone, and has been a Paris icon since 1889. 🗼 The Eiffel Tower isn't just our view, it's basically part of the team now. Catches every sunrise meeting, never misses the fun in the office, and definitely makes our Paris hub the most inspiring place to develop tomorrow's medicines.
Pages similaires
Parcourir les offres d’emploi
Financement
Ipsen
2 rounds en tout
Voir plus d’informations sur Crunchbase
Dernier round
Dette après introduction en Bourse
Lien Crunchbase externe pour la dernière levée de fonds
545 588 264,00 $US